Next Article in Journal
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Previous Article in Journal
From Biomarkers to Novel Therapeutic Approaches in Chronic Obstructive Pulmonary Disease
Article

LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients

1
Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
2
Department of Molecular Medicine, Central European Institute of Technology (CEITEC), Masaryk University, 625 00 Brno, Czech Republic
3
Department of Clinical Hematology, University Hospital Brno, 625 00 Brno, Czech Republic
4
Institute of Biostatistics and Analyses (IBA), Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic
5
Clinic of Internal Medicine, Hematology and Oncology, University Hospital Brno, 625 00 Brno, Czech Republic
*
Author to whom correspondence should be addressed.
Academic Editor: Jae Hoon Bahn
Biomedicines 2021, 9(11), 1637; https://doi.org/10.3390/biomedicines9111637
Received: 24 September 2021 / Revised: 24 October 2021 / Accepted: 4 November 2021 / Published: 8 November 2021
Long non-coding RNAs (lncRNAs) are functional RNAs longer than 200 nucleotides. Due to modern genomic techniques, the involvement of lncRNAs in tumorigenesis has been revealed; however, information concerning lncRNA interplay in multiple myeloma (MM) and plasma cell leukemia (PCL) is virtually absent. Herein, we aimed to identify the lncRNAs involved in MM to PCL progression. We investigated representative datasets of MM and PCL patients using next-generation sequencing. In total, 13 deregulated lncRNAs (p < 0.00025) were identified; four of them were chosen for further validation in an independent set of MM and PCL patients by RT-qPCR. The obtained results proved the significant downregulation of lymphocyte antigen antisense RNA 1 (LY86-AS1) and VIM antisense RNA 1 (VIM-AS1) in PCL compared to MM. Importantly, these two lncRNAs could be involved in the progression of MM into PCL; thus, they could serve as promising novel biomarkers of MM progression. View Full-Text
Keywords: multiple myeloma; plasma cell leukemia; long non-coding RNA; next-generation sequencing; biomarkers; disease progression multiple myeloma; plasma cell leukemia; long non-coding RNA; next-generation sequencing; biomarkers; disease progression
Show Figures

Figure 1

MDPI and ACS Style

Bútová, R.; Vychytilová-Faltejsková, P.; Gregorová, J.; Radová, L.; Almáši, M.; Bezděková, R.; Brožová, L.; Jarkovský, J.; Knechtová, Z.; Štork, M.; Pour, L.; Ševčíková, S. LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. Biomedicines 2021, 9, 1637. https://doi.org/10.3390/biomedicines9111637

AMA Style

Bútová R, Vychytilová-Faltejsková P, Gregorová J, Radová L, Almáši M, Bezděková R, Brožová L, Jarkovský J, Knechtová Z, Štork M, Pour L, Ševčíková S. LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients. Biomedicines. 2021; 9(11):1637. https://doi.org/10.3390/biomedicines9111637

Chicago/Turabian Style

Bútová, Romana, Petra Vychytilová-Faltejsková, Jana Gregorová, Lenka Radová, Martina Almáši, Renata Bezděková, Lucie Brožová, Jiří Jarkovský, Zdeňka Knechtová, Martin Štork, Luděk Pour, and Sabina Ševčíková. 2021. "LncRNAs LY86-AS1 and VIM-AS1 Distinguish Plasma Cell Leukemia Patients from Multiple Myeloma Patients" Biomedicines 9, no. 11: 1637. https://doi.org/10.3390/biomedicines9111637

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop